Back to School: How biopharma can reboot drug development. Access exclusive analysis here

OGX-427: Phase II started

OncoGenex said investigators at the Sarah Cannon Research Institute began the double-blind, placebo-controlled, U.S. Phase II Spruce

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE